The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

NCT06976619 on ClinicalTrials.gov · last registry update 2025-10-14

Recruiting now, toward 60 participants. Due to report 30 October 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment. Sponsors move these dates routinely; any movement since this site started watching is listed below. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 60
Started: 2025-10-03
Primary completion: 2028-10-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment

Conditions studied

Type 1 Diabetes · Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.